Trace Launches With $101m To Pursue ALS Drug Based On Genomic Insights

Could Address Up To 97% Of Patients

 
• By Mandy Jackson
  
Trace's lead drug candidate targets UNC13A mRNA splicing to treat ALS (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Scrip